Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Glycomimetics Inc (GLYC) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Glycomimetics Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1253689.
Total stock buying since 2014: $48,246,448.
Total stock sales since 2014: $15,474,524.
Total stock option exercises since 2014: $767,695.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 305,000 | $78,775 | 2,271,499 | $488,679 | 0 | $0 |
| 2023 | 2,035,620 | $3,935,847 | 4,003,876 | $12,508,748 | 31,500 | $39,374 |
| 2022 | 445,945 | $731,903 | 129,818 | $375,676 | 0 | $0 |
| 2021 | 40,000 | $82,000 | 0 | $0 | 0 | $0 |
| 2020 | 2,219,349 | $5,926,199 | 84,176 | $329,128 | 243,064 | $272,230 |
| 2019 | 1,678,746 | $5,341,749 | 0 | $0 | 273,743 | $306,592 |
| 2018 | 0 | $0 | 72,962 | $1,208,862 | 6,751 | $6,383 |
| 2017 | 0 | $0 | 8,000 | $111,440 | 8,928 | $9,999 |
| 2016 | 15,397 | $79,685 | 28,000 | $197,973 | 12,294 | $13,768 |
| 2015 | 0 | $0 | 1,808 | $12,492 | 5,000 | $5,600 |
| 2014 | 4,011,000 | $32,070,290 | 27,982 | $241,526 | 101,562 | $113,749 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-08 | 0 | $0 | 892,380 | $173,374 | 0 | $0 |
| 2024-07 | 0 | $0 | 1,379,119 | $315,305 | 0 | $0 |
| 2024-06 | 305,000 | $78,775 | 0 | $0 | 0 | $0 |
| 2023-09 | 65,403 | $90,255 | 0 | $0 | 0 | $0 |
| 2023-06 | 0 | $0 | 0 | $0 | 21,000 | $12,600 |
| 2023-05 | 43,500 | $67,995 | 3,700 | $7,215 | 0 | $0 |
| 2023-02 | 1,926,717 | $3,777,597 | 0 | $0 | 0 | $0 |
| 2023-01 | 0 | $0 | 4,000,176 | $12,501,533 | 10,500 | $26,774 |
| 2022-12 | 110,000 | $247,500 | 121,335 | $366,431 | 0 | $0 |
| 2022-11 | 335,945 | $484,403 | 0 | $0 | 0 | $0 |
| 2022-03 | 0 | $0 | 8,483 | $9,245 | 0 | $0 |
| 2021-11 | 40,000 | $82,000 | 0 | $0 | 0 | $0 |
| 2020-12 | 0 | $0 | 84,176 | $329,128 | 136,081 | $152,410 |
| 2020-11 | 1,266,737 | $3,293,516 | 0 | $0 | 0 | $0 |
| 2020-10 | 932,612 | $2,564,683 | 0 | $0 | 0 | $0 |
| 2020-03 | 20,000 | $68,000 | 0 | $0 | 0 | $0 |
| 2020-01 | 0 | $0 | 0 | $0 | 106,983 | $119,820 |
| 2019-12 | 0 | $0 | 0 | $0 | 106,984 | $119,822 |
| 2019-09 | 1,668,746 | $5,309,949 | 0 | $0 | 0 | $0 |
| 2019-08 | 10,000 | $31,800 | 0 | $0 | 166,759 | $186,770 |
| 2018-10 | 0 | $0 | 25,000 | $350,212 | 0 | $0 |
| 2018-06 | 0 | $0 | 19,345 | $348,983 | 5,260 | $5,891 |
| 2018-05 | 0 | $0 | 28,617 | $509,667 | 1,491 | $492 |
| 2017-12 | 0 | $0 | 2,000 | $30,020 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-08-08 | Debbane Raymond | Sale | 260,873 | .19 | 50,087 |
| 2024-08-07 | Debbane Raymond | Sale | 61,488 | .18 | 11,190 |
| 2024-08-06 | Debbane Raymond | Sale | 55,732 | .18 | 10,198 |
| 2024-08-05 | Debbane Raymond | Sale | 164,523 | .19 | 30,930 |
| 2024-08-02 | Debbane Raymond | Sale | 286,200 | .20 | 57,240 |
| 2024-08-01 | Debbane Raymond | Sale | 63,564 | .22 | 13,729 |
| 2024-07-30 | Debbane Raymond | Sale | 756,835 | .22 | 167,260 |
| 2024-07-29 | Debbane Raymond | Sale | 363,949 | .23 | 85,528 |
| 2024-07-26 | Debbane Raymond | Sale | 258,335 | .24 | 62,517 |
| 2024-06-21 | Rock Edwin (Chief Medical Officer) | Buy | 115,000 | .27 | 30,705 |
| 2024-06-20 | Rock Edwin (Chief Medical Officer) | Buy | 190,000 | .25 | 48,070 |
| 2023-09-22 | Rock Edwin (Chief Medical Officer) | Buy | 30,403 | 1.38 | 41,956 |
| 2023-09-21 | Rock Edwin (Chief Medical Officer) | Buy | 35,000 | 1.38 | 48,299 |
| 2023-06-01 | Koenig Scott (Director) | Option Ex | 21,000 | .60 | 12,600 |
| 2023-05-17 | Hahn Brian M. (SVP Finance, CFO) | Sale | 3,700 | 1.95 | 7,215 |
| 2023-05-10 | Junius Daniel M (Director) | Buy | 30,000 | 1.56 | 46,800 |
| 2023-05-08 | Johnson Bruce S (SVP & Chief Commercial Officer) | Buy | 13,500 | 1.57 | 21,195 |
| 2023-02-23 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 200,000 | 1.75 | 350,800 |
| 2023-02-22 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 150,000 | 1.79 | 268,950 |
| 2023-02-21 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 50,000 | 1.85 | 92,500 |
| 2023-02-17 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 200,000 | 1.71 | 341,000 |
| 2023-02-16 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 315,266 | 1.69 | 531,223 |
| 2023-02-15 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 1,000,000 | 2.16 | 2,156,000 |
| 2023-02-09 | Invus Public Equities Advisors, Llc (10% Owner) | Buy | 11,451 | 3.24 | 37,124 |
| 2023-01-27 | Koenig Scott (Director) | Option Ex | 10,500 | 2.55 | 26,774 |
| 2023-01-26 | Sandell Scott D (10% Owner) | Sale | 3,000,000 | 3.12 | 9,357,000 |
| 2023-01-25 | Sandell Scott D (10% Owner) | Sale | 652,016 | 3.26 | 2,128,180 |
| 2023-01-05 | Sandell Scott D (10% Owner) | Sale | 71,362 | 2.76 | 196,887 |
| 2023-01-04 | Sandell Scott D (10% Owner) | Sale | 101,984 | 2.91 | 296,773 |
| 2023-01-03 | Sandell Scott D (10% Owner) | Sale | 174,814 | 2.99 | 522,693 |
| 2022-12-30 | Sandell Scott D (10% Owner) | Sale | 121,335 | 3.02 | 366,431 |
| 2022-12-22 | Rock Edwin (Chief Medical Officer) | Buy | 110,000 | 2.25 | 247,500 |
| 2022-11-17 | Junius Daniel M (Director) | Buy | 20,000 | 1.87 | 37,400 |
| 2022-11-15 | Rock Edwin (Chief Medical Officer) | Buy | 100,000 | 1.66 | 166,000 |
| 2022-11-14 | Rock Edwin (Chief Medical Officer) | Buy | 100,000 | 1.43 | 143,000 |
| 2022-11-11 | Semerjian Harout (Chief Executive Officer) | Buy | 25,000 | 1.29 | 32,250 |
| 2022-11-11 | Girard Armand (SVP, Chief Business Officer) | Buy | 6,500 | 1.05 | 6,825 |
| 2022-11-11 | Magnani John L. (SVP of Research, CSO) | Buy | 45,045 | 1.17 | 52,702 |
| 2022-11-11 | Hahn Brian M. (SVP Finance, CFO) | Buy | 20,000 | 1.06 | 21,200 |
| 2022-11-11 | Pearson Timothy R (Director) | Buy | 19,400 | 1.29 | 25,026 |
| 2022-03-09 | Girard Armand (SVP, Chief Business Officer) | Sale | 2,339 | 1.09 | 2,549 |
| 2022-03-09 | Magnani John L. (SVP of Research, CSO) | Sale | 3,227 | 1.09 | 3,517 |
| 2022-03-09 | Hahn Brian M. (SVP Finance, CFO) | Sale | 2,917 | 1.09 | 3,179 |
| 2021-11-16 | Andrews Patricia S (Director) | Buy | 40,000 | 2.05 | 82,000 |
| 2020-12-28 | King Rachel K. (President, CEO) | Sale | 84,176 | 3.91 | 329,128 |
| 2020-12-28 | King Rachel K. (President, CEO) | Option Ex | 130,821 | 1.12 | 146,519 |
| 2020-12-16 | Hahn Brian M. (SVP Finance, CFO) | Option Ex | 5,260 | 1.12 | 5,891 |
| 2020-11-04 | Lampert Mark N | Buy | 1,266,737 | 2.60 | 3,293,516 |
| 2020-10-30 | Lampert Mark N | Buy | 932,612 | 2.75 | 2,564,683 |
| 2020-03-09 | Junius Daniel M (Director) | Buy | 20,000 | 3.40 | 68,000 |
| 2020-01-06 | Magnani John L. (SVP of Research, CSO) | Option Ex | 106,983 | 1.12 | 119,820 |
| 2019-12-20 | Magnani John L. (SVP of Research, CSO) | Option Ex | 106,984 | 1.12 | 119,822 |
| 2019-09-05 | Lampert Mark N | Buy | 1,668,746 | 3.18 | 5,309,949 |
| 2019-08-13 | Junius Daniel M (Director) | Buy | 10,000 | 3.18 | 31,800 |
| 2019-08-06 | King Rachel K. (President, CEO) | Option Ex | 166,759 | 1.12 | 186,770 |
| 2018-10-18 | Magnani John L. (SVP of Research, CSO) | Sale | 3,527 | 14.02 | 49,448 |
| 2018-10-17 | Magnani John L. (SVP of Research, CSO) | Sale | 7,273 | 14.00 | 101,822 |
| 2018-10-16 | Magnani John L. (SVP of Research, CSO) | Sale | 14,200 | 14.01 | 198,942 |
| 2018-06-11 | Hahn Brian M. (CFO) | Sale | 19,345 | 18.04 | 348,983 |
| 2018-06-11 | Hahn Brian M. (CFO) | Option Ex | 5,260 | 1.12 | 5,891 |
| 2018-05-23 | Magnani John L. (SVP of Research, CSO) | Option Ex | 1,491 | .33 | 492 |
| 2018-05-10 | Nea Partners 10 L P (10% Owner) | Sale | 9,539 | 17.81 | 169,889 |
| 2018-05-10 | Barrett M James (Director) | Sale | 9,539 | 17.81 | 169,889 |
| 2018-05-10 | Barris Peter J (10% Owner) | Sale | 9,539 | 17.81 | 169,889 |
| 2017-12-08 | Thackray Helen M. (SVP Clinical Development, CMO) | Sale | 2,000 | 15.01 | 30,020 |
| 2017-09-18 | Thackray Helen M. (SVP Clinical Development, CMO) | Sale | 2,000 | 13.00 | 26,000 |
| 2017-05-25 | Thackray Helen M. (SVP Clinical Development, CMO) | Sale | 2,000 | 15.57 | 31,140 |
| 2017-05-19 | Thackray Helen M. (SVP Clinical Development, CMO) | Sale | 2,000 | 12.14 | 24,280 |
| 2017-05-10 | Magnani John L. (SVP of Research, CSO) | Option Ex | 8,928 | 1.12 | 9,999 |
| 2016-12-20 | Junius Daniel M (Director) | Buy | 5,000 | 6.01 | 30,050 |
| 2016-10-03 | Thackray Helen M. (VP Clinical Development, CMO) | Sale | 4,000 | 7.00 | 28,020 |
| 2016-07-20 | Thackray Helen M. (VP Clinical Development, CMO) | Sale | 2,000 | 8.00 | 16,000 |
| 2016-07-06 | Thackray Helen M. (VP Clinical Development, CMO) | Sale | 6,796 | 6.68 | 45,397 |
| 2016-07-05 | Thackray Helen M. (VP Clinical Development, CMO) | Sale | 10,136 | 7.01 | 71,053 |
| 2016-07-01 | Thackray Helen M. (VP Clinical Development, CMO) | Sale | 5,068 | 7.40 | 37,503 |
| 2016-06-29 | Baldwin John J. (Director) | Option Ex | 605 | 1.12 | 677 |
| 2016-03-04 | Goldberg Mark Alan (Director) | Buy | 10,397 | 4.77 | 49,635 |
| 2016-02-05 | Top Franklin H Jr (Director) | Option Ex | 11,689 | 1.12 | 13,091 |
| 2015-11-16 | Sandell Scott D (10% Owner) | Sale | 452 | 6.91 | 3,123 |
| 2015-11-16 | Nea Partners 10 L P (10% Owner) | Sale | 452 | 6.91 | 3,123 |
| 2015-11-16 | Barrett M James (Director) | Sale | 452 | 6.91 | 3,123 |
| 2015-11-16 | Barris Peter J (10% Owner) | Sale | 452 | 6.91 | 3,123 |
| 2015-02-27 | Hahn Brian M. (CFO) | Option Ex | 5,000 | 1.12 | 5,600 |
| 2014-12-22 | Henos Michael A (Director) | Sale | 10,659 | 8.44 | 89,908 |
| 2014-12-19 | Henos Michael A (Director) | Sale | 10,598 | 8.61 | 91,280 |
| 2014-12-17 | Henos Michael A (Director) | Sale | 5,121 | 8.97 | 45,935 |
| 2014-12-15 | Henos Michael A (Director) | Sale | 1,604 | 8.98 | 14,403 |
| 2014-06-18 | King Rachel K. (President, CEO) | Option Ex | 100,000 | 1.12 | 112,000 |
| 2014-06-13 | Henos Michael A (Director) | Buy | 5,000 | 6.21 | 31,050 |
| 2014-06-12 | Henos Michael A (Director) | Buy | 6,000 | 6.54 | 39,240 |
| 2014-04-03 | Henos Michael A (Director) | Option Ex | 1,562 | 1.12 | 1,749 |
| 2014-01-15 | Weller Harry R (10% Owner) | Buy | 512,500 | 8.00 | 4,100,000 |
| 2014-01-15 | Sandell Scott D (10% Owner) | Buy | 1,000,000 | 8.00 | 8,000,000 |
| 2014-01-15 | Nea Partners 10 L P (10% Owner) | Buy | 487,500 | 8.00 | 3,900,000 |
| 2014-01-15 | Barrett M James (Director) | Buy | 1,000,000 | 8.00 | 8,000,000 |
| 2014-01-15 | Barris Peter J (10% Owner) | Buy | 1,000,000 | 8.00 | 8,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of GLYC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Glycomimetics Inc (symbol GLYC, CIK number 1253689) see the Securities and Exchange Commission (SEC) website.